Key Developments: WuXi Pharmatech (Cayman) Inc (WX)
20.43USD
17 May 2013
$0.11 (+0.54%)
$20.32
$20.21
$20.48
$20.08
361,020
342,997
$21.14
$13.00
Latest Key Developments (Source: Significant Developments)
Wuxi Pharmatech (Cayman) Inc Reaffirms FY 2013 Guidance; Issues Q2 2013 Guidance Below Analysts' Estimates
Wuxi Pharmatech (Cayman) Inc announced that for fiscal 2013, it expects total net revenues of $565-575 million, GAAP diluted earnings per ADS of $1.26-$1.30 and Non-GAAP diluted earnings per ADS of $1.49-$1.53. For the second quarter of 2013, it expects total net revenues of $138-140 million, GAAP diluted earnings per ADS of $0.34-$0.35 and Non-GAAP diluted earnings per ADS of $0.39-$0.40. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $573 million and EPS of $1.47 for fiscal 2013; revenue of $142 million and EPS of $0.36 for the second quarter of 2013. Full Article
Wuxi Pharmatech (Cayman) Inc Issues Q1 2013 Guidance In Line With Analysts' Estimates; Issues FY 2013 Guidance; EPS Guidance Above Analysts' Estimates
Wuxi Pharmatech (Cayman) Inc announced that for fiscal 2013, it expects total net revenues of $565-575 million, GAAP diluted earnings per ADS of $1.26-$1.30 and Non-GAAP diluted earnings per ADS of $1.49-$1.53. For the first quarter of 2013, it expects total net revenues of $129-131 million, GAAP diluted earnings per ADS of $0.26-$0.27 and non-GAAP diluted earnings per ADS of $0.31-$0.32. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $572 million and EPS of $1.44 for fiscal 2013; revenue of $131 million and EPS of $0.31 for the first quarter of 2013. Full Article
Wuxi Pharmatech (Cayman) Inc Revises FY 2012 Guidance To A Range In Line With Analysts' Estimates
Wuxi Pharmatech (Cayman) Inc announced that based on preliminary, unaudited results, it expects to achieve total revenues of approximately $500 million and to meet the remainder of fiscal 2012 financial guidance found in its third-quarter 2012 earnings release. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $497 million for fiscal 2012. Full Article
Wuxi Pharmatech (Cayman) Inc And PRA Form Joint Venture To Offer Clinical Research Services For Chinese Market
Wuxi Pharmatech (Cayman) Inc and PRA, a global clinical contract research organization, announced that they have signed a joint venture agreement to offer a broad platform of Phase I-IV clinical trial services in China , Hong Kong and Macau. The joint venture will provide services including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting, and medical monitoring. The clinical operations of WuXi and PRA in China will combine to operate as an independent CRO and will be jointly owned by their respective parent companies. WuXi will contribute clinical and regulatory experience to the joint venture from its China -based clinical organization. That organization covers all regions of the country and has employees working in 16 Chinese cities, with offices in Shanghai , Beijing and Guangzhou . WuXi will also supply laboratory services to the joint venture through a preferred provider arrangement. PRA offers the venture a wealth of global resources and clinical research expertise, reflected in more than 3,100 studies conducted over the last five years and contributions to 40 approved drugs in several therapeutic areas. PRA will also support the venture with its China -based staff and global technology capabilities, encompassing data capture, trial management and other IT systems. The companies will market the joint venture's services to their respective customers. Full Article
Wuxi Pharmatech (Cayman) Inc Issues Q4 2012 Revenue Guidance In Line With Analysts' Estimates; Raises Low End Of Prior FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates
Wuxi Pharmatech (Cayman) Inc announced that for the fourth quarter of 2012, it expects total net revenues of $121-124 million. For fiscal 2012, it expects total net revenues of $495-498 million, compared to previous guidance of $488-498 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $497 million for fiscal 2012; revenues of $124 million for the fourth quarter of 2012. Full Article
Wuxi Pharmatech (Cayman) Inc And Open Monoclonal Technology Announce OmniRat Antibody Collaboration
WuXi PharmaTech (Cayman) Inc and Open Monoclonal Technology, Inc announced that they have entered into an agreement to use OMT's OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi's global customers. Full Article
Wuxi Pharmatech (Cayman) Inc To Manufacture Ibalizumab For TaiMed Biologics Inc
Wuxi Pharmatech (Cayman) Inc announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally. Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States. Full Article
Wuxi Pharmatech (Cayman) Inc Raises FY 2012 Revenue Guidance
Wuxi Pharmatech (Cayman) Inc announced that for fiscal 2012, it raises net revenue guidance to the range of $488 to $498 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $484 million for fiscal 2012. Full Article
WuXi PharmaTech (Cayman) Inc. Reaffirms FY 2012 Revenue Guidance
WuXi PharmaTech (Cayman) Inc. reaffirmed fiscal 2012 revenue guidance to a range $468-$488 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $478 million for fiscal 2012. Full Article
WuXi PharmaTech (Cayman) Inc. Issues Q1, FY 2012 Revenue Guidance Above Analysts' Estimates
WuXi PharmaTech (Cayman) Inc. announced that for fiscal 2012, it expects net revenues of $468-$488 million. For the first quarter of 2012 it expects total revenues of $114-$117 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $465 million for fiscal 2012; revenues of $108 million for the first quarter of 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
